vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and Lucid Diagnostics Inc. (LUCD). Click either name above to swap in a different company.
GAXOS.AI INC. is the larger business by last-quarter revenue ($1.2M vs $1.2M, roughly 1.0× Lucid Diagnostics Inc.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -858.5%, a 781.3% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs 3.3%).
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.
GXAI vs LUCD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.2M |
| Net Profit | $-957.9K | $-10.4M |
| Gross Margin | — | — |
| Operating Margin | -99.0% | -971.0% |
| Net Margin | -77.2% | -858.5% |
| Revenue YoY | 94996.3% | 3.3% |
| Net Profit YoY | -15.1% | 16.0% |
| EPS (diluted) | $-0.13 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $498.3K | $1.2M | ||
| Q2 25 | $171.0K | $1.2M | ||
| Q1 25 | — | $828.0K | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | $0 | $976.0K | ||
| Q1 24 | — | $1.0M |
| Q4 25 | $-957.9K | — | ||
| Q3 25 | $-1.0M | $-10.4M | ||
| Q2 25 | $-749.4K | $-4.4M | ||
| Q1 25 | — | $-26.9M | ||
| Q4 24 | — | $-11.5M | ||
| Q3 24 | — | $-12.4M | ||
| Q2 24 | $-809.2K | $-11.0M | ||
| Q1 24 | — | $-10.6M |
| Q4 25 | -99.0% | — | ||
| Q3 25 | -263.9% | -971.0% | ||
| Q2 25 | -574.8% | -978.8% | ||
| Q1 25 | — | -1508.1% | ||
| Q4 24 | — | -1033.8% | ||
| Q3 24 | — | -997.8% | ||
| Q2 24 | — | -1146.7% | ||
| Q1 24 | — | -1078.1% |
| Q4 25 | -77.2% | — | ||
| Q3 25 | -201.0% | -858.5% | ||
| Q2 25 | -438.3% | -381.7% | ||
| Q1 25 | — | -3249.8% | ||
| Q4 24 | — | -964.2% | ||
| Q3 24 | — | -1055.5% | ||
| Q2 24 | — | -1127.6% | ||
| Q1 24 | — | -1060.1% |
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.14 | $-0.10 | ||
| Q2 25 | $-0.11 | $-0.08 | ||
| Q1 25 | — | $-0.52 | ||
| Q4 24 | — | $-0.17 | ||
| Q3 24 | — | $-0.25 | ||
| Q2 24 | $-0.72 | $-0.23 | ||
| Q1 24 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $47.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $25.8M |
| Total Assets | $13.4M | $53.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | — | ||
| Q3 25 | — | $47.3M | ||
| Q2 25 | — | $31.1M | ||
| Q1 25 | — | $25.2M | ||
| Q4 24 | — | $22.4M | ||
| Q3 24 | — | $14.5M | ||
| Q2 24 | $4.5M | $24.9M | ||
| Q1 24 | — | $24.8M |
| Q4 25 | $13.1M | — | ||
| Q3 25 | $14.1M | $25.8M | ||
| Q2 25 | $15.0M | $7.9M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $4.7M | $16.0M | ||
| Q1 24 | — | $11.9M |
| Q4 25 | $13.4M | — | ||
| Q3 25 | $14.3M | $53.2M | ||
| Q2 25 | $15.4M | $38.7M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $22.6M | ||
| Q2 24 | $5.1M | $34.1M | ||
| Q1 24 | — | $32.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | $-10.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | — | ||
| Q3 25 | $-1.1M | $-10.9M | ||
| Q2 25 | $-716.9K | $-10.5M | ||
| Q1 25 | — | $-12.5M | ||
| Q4 24 | — | $-9.9M | ||
| Q3 24 | — | $-10.2M | ||
| Q2 24 | $-738.5K | $-11.5M | ||
| Q1 24 | — | $-12.6M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
